CTCL
10
2
3
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
30.0%
3 terminated out of 10 trials
40.0%
-46.6% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (10)
StrataCTX® as a Steroid Sparing Device
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Ritlecitinib in CTCL
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL